{
    "Trade/Device Name(s)": [
        "Vysis CLL FISH Probe Kit"
    ],
    "Submitter Information": "Abbott Molecular Inc.",
    "510(k) Number": "K100015",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062694"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OVQ"
    ],
    "Summary Letter Date": "July 21, 2011",
    "Summary Letter Received Date": "July 22, 2011",
    "Submission Date": "August 9, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "hematology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "TP53 (tumor protein p53 gene)",
        "ATM (ataxia telangiectasia mutated gene)",
        "D13S319 marker",
        "D12Z3 sequence",
        "13q34 (lysosomal-associated membrane protein I gene)"
    ],
    "Specimen Type(s)": [
        "Peripheral blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Fluorescence microscope"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence in situ hybridization (FISH)",
        "DNA probe hybridization"
    ],
    "Methodologies": [
        "Chromosomal abnormality detection",
        "Gene copy number determination"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Probe"
    ],
    "Document Summary": "FDA 510(k) summary for Vysis CLL FISH Probe Kit utilizing FISH DNA probes to detect chromosomal deletions and trisomy in peripheral blood from untreated CLL patients to aid in prognosis.",
    "Indications for Use Summary": "Detects deletion of LSI TP53, LSI ATM, LSI D13S319 probe targets and gain of D12Z3 sequence in peripheral blood from untreated B-cell CLL patients, used to dichotomize CLL prognosis in conjunction with additional biomarkers, morphology, and clinical information; not for therapy selection or disease monitoring.",
    "fda_folder": "Immunology"
}